XML 88 R36.htm IDEA: XBRL DOCUMENT
v3.26.1

Contract revenues and other operating income - Anti-Abeta Active Immunotherapy in AD - 2024 agreement Takeda Pharmaceuticals, USA Inc. (Details) SFr in Thousands, $ in Millions | 1 Months Ended | 6 Months Ended |
--- | --- | --- | ---
May 31, 2024 CHF (SFr) | May 31, 2024 USD ($) | Jun. 30, 2026 CHF (SFr) | Jun. 30, 2025 CHF (SFr) | May 31, 2024 USD ($)
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |  |  |
Contract revenue |  |  | SFr 16,232 | SFr 2,296 |
Anti-Abeta Active Immunotherapy in AD- 2024 agreement Takeda Pharmaceuticals, USA, Inc. |  |  |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |  |  |
Collaborative agreement, upfront payments received | SFr 92,300 | $ 100.0 |  |  |
Period to provide notice of termination of agreement | 90 days | 90 days |  |  |
Transaction price | SFr 92,300 |  |  |  | $ 100.0
Number of development milestones that may occur prior to option exercise included in transaction price | 0 |  |  |  | 0
Contract revenue |  |  | 2,100 |  |
Deferred revenue |  |  | SFr 84,000 |  |
Anti-Abeta Active Immunotherapy in AD- 2024 agreement Takeda Pharmaceuticals, USA, Inc. | License option and development, CMC and regulatory activities |  |  |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |  |  |
Transaction price | SFr 92,300 |  |  |  | $ 100.0
Anti-Abeta Active Immunotherapy in AD- 2024 agreement Takeda Pharmaceuticals, USA, Inc. | License option |  |  |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |  |  |
Transaction price | SFr 80,700 |  |  |  | 87.4
Anti-Abeta Active Immunotherapy in AD- 2024 agreement Takeda Pharmaceuticals, USA, Inc. | Development, CMC and regulatory activities |  |  |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |  |  |
Number of performance obligations identified | 1 | 1 |  |  |
Transaction price | SFr 11,600 |  |  |  | 12.6
Anti-Abeta Active Immunotherapy in AD- 2024 agreement Takeda Pharmaceuticals, USA, Inc. | Maximum |  |  |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |  |  |
Collaborative agreement, potential amount receivable if certain conditions are fulfilled | SFr 1,700,000 |  |  |  | $ 2,100.0

X
- Definition Period of time that notice is required to be given for cancellation of the collaborative agreement contract, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | aciu_CollaborativeAgreementNoticeOfContractTerminationPeriod
Namespace Prefix: | aciu_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative agreement, potential amount receivable if certain conditions are fulfilled. + References No definition available. + Details
Name: | aciu_CollaborativeAgreementPotentialAmountReceivableIfCertainConditionsAreFulfilled
Namespace Prefix: | aciu_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Collaborative agreement, upfront payments received + References No definition available. + Details
Name: | aciu_CollaborativeAgreementUpfrontPaymentsReceived
Namespace Prefix: | aciu_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of development milestones that may occur prior to option exercise included in transaction price + References No definition available. + Details
Name: | aciu_NumberOfDevelopmentMilestonesThatMayOccurPriorToOptionExerciseIncludedInTransactionPrice
Namespace Prefix: | aciu_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition The number of performance obligations identified applicable to the entity's assessment of a specific contractual arrangement. + References No definition available. + Details
Name: | aciu_NumberOfPerformanceObligationsIdentified
Namespace Prefix: | aciu_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of an entity’s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2025-01-01 -Paragraph 105 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_105&doctype=Standard -URIDate 2025-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2025-01-01 -Paragraph 116 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_116_a&doctype=Standard -URIDate 2025-03-27 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Note Effective 2027-01-01 -Name IFRS -Number 19 -IssueDate 2025-01-01 -Paragraph 105 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_105_a&doctype=Standard -URIDate 2025-03-27 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Note Effective 2027-01-01 -Name IFRS -Number 19 -IssueDate 2025-01-01 -Paragraph 105 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_105_a&doctype=Standard -URIDate 2025-03-27 + Details
Name: | ifrs-full_ContractLiabilities
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2025-01-01 -Paragraph 114 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_114&doctype=Standard -URIDate 2025-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2025-01-01 -Paragraph 113 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_113_a&doctype=Standard -URIDate 2025-03-27 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Note Effective 2027-01-01 -Name IFRS -Number 19 -IssueDate 2025-01-01 -Paragraph 103 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103&doctype=Standard -URIDate 2025-03-27 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Note Effective 2027-01-01 -Name IFRS -Number 19 -IssueDate 2025-01-01 -Paragraph 103 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103&doctype=Standard -URIDate 2025-03-27 + Details
Name: | ifrs-full_RevenueFromContractsWithCustomers
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of the transaction price allocated to the performance obligations that are unsatisfied (or partially unsatisfied) as of the end of the reporting period. The transaction price is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties (for example, some sales taxes). [Refer: Performance obligations [domain]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2025-01-01 -Paragraph 120 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_120_a&doctype=Standard -URIDate 2025-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Note Effective 2027-01-01 -Name IFRS -Number 19 -IssueDate 2025-01-01 -Paragraph 108 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_108_a&doctype=Standard -URIDate 2025-03-27 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Note Effective 2027-01-01 -Name IFRS -Number 19 -IssueDate 2025-01-01 -Paragraph 108 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_108_a&doctype=Standard -URIDate 2025-03-27 + Details
Name: | ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | ifrs-full_TypesOfContractsAxis=aciu_AntiAbetaActiveImmunotherapyInAd2024AgreementTakedaPharmaceuticalsUsaInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_PerformanceObligationsAxis=aciu_LicenseOptionAndDevelopmentCmcAndRegulatoryActivitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_PerformanceObligationsAxis=aciu_LicenseOptionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_PerformanceObligationsAxis=aciu_DevelopmentCmcAndRegulatoryActivitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |